Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis
-
Add time:07/24/2019 Source:sciencedirect.com
Drugs currently available for visceral leishmaniasis treatment are potentially toxic, have to be administered by parenteral route and frequently give rise to drug resistance, due to the involvement of P-glycoproteins (P-gp) in Leishmania. The purpose of this study was to investigate a possible inhibitory effect of 2n-propylquinoline (2nPQ) on P-gp activity. 2nPQ is a new oral anti-leishmanial drug that has demonstrated its efficacy in BALB/c infected mice with Leishmania donovani [Antimicrob. Agents Chemother. 37 (1993) 859]. Rat everted gut sacs and human intestinal Caco-2 cell lines were used to study the effect of 2nPQ on P-gp activity. Our results demonstrate an inhibitory effect of 2nPQ on the P-gp activity with two P-gp substrates (rhodamine 123 and digoxin), two P-gp inhibitors (cyclosporin A and verapamil), and in two different species. Alone or associated with other active drugs, 2nPQ would be very useful to control Leishmania Multi-Drug-Resistance and intestinal P-gp in humans with kala-azar.Index Descriptors and Abbreviations: VL, visceral leishmaniasis; 2nPQ, 2n-propylquinoline; P-gp, P-glycoprotein; MDR, Multi-Drug-Resistance; Caco-2 cells, human colon adenocarcinoma cell line; BALB/c, Consanguine mouse; HIV, human immunodeficiency virus; DMEM, Dulbecco’s modified Eagle’s medium; PBS, phosphate-buffered salt Galipea longiflora, Rutaceae plant rat; everted gut sacs; LD50, lethal dose 50.
We also recommend Trading Suppliers and Manufacturers of 2-propylquinoline (cas 1613-32-7). Pls Click Website Link as below: cas 1613-32-7 suppliers
Prev:Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials
Next:Towards oxidative denitrogenation of fuel oils: Vanadium oxide-catalysed oxidation of quinoline and adsorptive removal of Quinoline-N-oxide (cas 1613-37-2) using 2,6-pyridine-polybenzimidazole nanofibers) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials07/23/2019
- Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography07/22/2019
- In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route07/20/2019
- Straightforward synthesis of 2-propylquinoline (cas 1613-32-7)s under multicomponent conditions in fluorinated alcohols07/21/2019
- Microwave-assisted synthesis and antibacterial propensity of N′-s-benzylidene-2-propylquinoline (cas 1613-32-7)-4-carbohydrazide and N′-((s-1H-pyrrol-2-yl)methylene)-2-propylquinoline (cas 1613-32-7)-4-carbohydrazide motifs07/19/2019


